These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 28692197)

  • 1. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.
    Chitturi S; Wong VW; Chan WK; Wong GL; Wong SK; Sollano J; Ni YH; Liu CJ; Lin YC; Lesmana LA; Kim SU; Hashimoto E; Hamaguchi M; Goh KL; Fan J; Duseja A; Dan YY; Chawla Y; Farrell G; Chan HL
    J Gastroenterol Hepatol; 2018 Jan; 33(1):86-98. PubMed ID: 28692197
    [No Abstract]   [Full Text] [Related]  

  • 2. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.
    Wong VW; Chan WK; Chitturi S; Chawla Y; Dan YY; Duseja A; Fan J; Goh KL; Hamaguchi M; Hashimoto E; Kim SU; Lesmana LA; Lin YC; Liu CJ; Ni YH; Sollano J; Wong SK; Wong GL; Chan HL; Farrell G
    J Gastroenterol Hepatol; 2018 Jan; 33(1):70-85. PubMed ID: 28670712
    [No Abstract]   [Full Text] [Related]  

  • 3. Position statement on the diagnosis and management of non-alcoholic fatty liver disease.
    Alswat KA; Fallatah HI; Al-Judaibi B; Elsiesy HA; Al-Hamoudi WK; Qutub AN; Alturaify N; Al-Osaimi A
    Saudi Med J; 2019 Jun; 40(6):531-540. PubMed ID: 31219486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
    Mathews SE; Kumar RB; Shukla AP
    Curr Opin Endocrinol Diabetes Obes; 2018 Oct; 25(5):315-320. PubMed ID: 30074500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].
    Pár A; Pár G
    Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.
    Leoni S; Tovoli F; Napoli L; Serio I; Ferri S; Bolondi L
    World J Gastroenterol; 2018 Aug; 24(30):3361-3373. PubMed ID: 30122876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current management of non-alcoholic fatty liver disease.
    Lisboa QC; Costa SM; Couto CA
    Rev Assoc Med Bras (1992); 2016 Dec; 62(9):872-878. PubMed ID: 28001263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
    J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How should we manage patients with non-alcoholic fatty liver disease in 2007?
    Chan HL; de Silva HJ; Leung NW; Lim SG; Farrell GC;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):801-8. PubMed ID: 17565632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
    Ahmed A; Wong RJ; Harrison SA
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
    Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
    Argyrou C; Moris D; Vernadakis S
    J BUON; 2017; 22(1):6-20. PubMed ID: 28365930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future treatment options in non-alcoholic steatohepatitis (NASH).
    Lazaridis N; Tsochatzis E
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):357-369. PubMed ID: 28276821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE; Rinella ME
    Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Non-alcoholic fatty liver disease and steatohepatitis].
    Pár G; Horváth G; Pár A
    Orv Hetil; 2013 Jul; 154(29):1124-34. PubMed ID: 23853345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management and diagnosis of fatty liver disease.
    Schneier AT; Citti CC; Dieterich DT
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):671-83. PubMed ID: 25716275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current solutions for obesity-related liver disorders: non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Raziel A; Sakran N; Szold A; Goitein D
    Isr Med Assoc J; 2015 Apr; 17(4):234-8. PubMed ID: 26040050
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.